📊 TECH Key Takeaways
Is BIO-TECHNE Corp (TECH) a Good Investment?
BIO-TECHNE exhibits strong financial health with excellent liquidity, conservative leverage, and robust free cash flow generation, but faces serious growth challenges with zero revenue expansion and significant EPS dilution. While profitability remains solid with 65.1% gross margins and 13.1% net margins, the company is destroying shareholder value through dilution and generating poor returns on capital (3.8% ROE, 3.0% ROA), suggesting capital is not being deployed effectively.
Why Buy BIO-TECHNE Corp Stock? TECH Key Strengths
- Excellent gross margins at 65.1% demonstrating strong pricing power and operational efficiency
- Strong free cash flow generation of $98.7M with 16.9% FCF margin and minimal capital intensity
- Fortress balance sheet with 4.54x current ratio, 0.13x debt/equity ratio, and 7.7x interest coverage ratio
TECH Stock Risks: BIO-TECHNE Corp Investment Risks
- Complete revenue stagnation at 0.0% YoY growth with flat net income, indicating loss of market momentum
- Severe EPS dilution of 56.2% YoY despite stable earnings, destroying shareholder value
- Very poor capital efficiency with 3.8% ROE and 3.0% ROA, suggesting ineffective capital deployment and growth investments
Key Metrics to Watch
- Revenue growth rate and new product/market expansion progress
- Share count trajectory and dilution rate alongside EPS trends
- ROE and ROA improvement as indicators of better capital allocation and operational leverage
BIO-TECHNE Corp (TECH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.54x current ratio provides a solid financial cushion.
TECH Profit Margin, ROE & Profitability Analysis
TECH vs Healthcare Sector: How BIO-TECHNE Corp Compares
How BIO-TECHNE Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BIO-TECHNE Corp Stock Overvalued? TECH Valuation Analysis 2026
Based on fundamental analysis, BIO-TECHNE Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BIO-TECHNE Corp Balance Sheet: TECH Debt, Cash & Liquidity
TECH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BIO-TECHNE Corp's revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.76 reflects profitable operations.
TECH Revenue Growth, EPS Growth & YoY Performance
TECH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $295.9M | $34.9M | $0.22 |
| Q1 2026 | $286.6M | $33.6M | $0.21 |
| Q3 2025 | $303.4M | $22.6M | $0.14 |
| Q2 2025 | $272.6M | $27.5M | $0.17 |
| Q1 2025 | $276.9M | $33.6M | $0.21 |
| Q3 2024 | $294.1M | $49.1M | $0.31 |
| Q2 2024 | $271.6M | $27.5M | $0.17 |
| Q1 2024 | $269.7M | $51.0M | $0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIO-TECHNE Corp Dividends, Buybacks & Capital Allocation
TECH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BIO-TECHNE Corp (CIK: 0000842023)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TECH
What is the AI rating for TECH?
BIO-TECHNE Corp (TECH) has an AI rating of HOLD with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TECH's key strengths?
Claude: Excellent gross margins at 65.1% demonstrating strong pricing power and operational efficiency. Strong free cash flow generation of $98.7M with 16.9% FCF margin and minimal capital intensity.
What are the risks of investing in TECH?
Claude: Complete revenue stagnation at 0.0% YoY growth with flat net income, indicating loss of market momentum. Severe EPS dilution of 56.2% YoY despite stable earnings, destroying shareholder value.
What is TECH's revenue and growth?
BIO-TECHNE Corp reported revenue of $582.4M.
Does TECH pay dividends?
BIO-TECHNE Corp pays dividends, with $24.9M distributed to shareholders in the trailing twelve months.
Where can I find TECH SEC filings?
Official SEC filings for BIO-TECHNE Corp (CIK: 0000842023) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TECH's EPS?
BIO-TECHNE Corp has a diluted EPS of $0.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TECH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BIO-TECHNE Corp has a HOLD rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TECH stock overvalued or undervalued?
Valuation metrics for TECH: ROE of 3.8% (sector avg: 15%), net margin of 13.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TECH stock in 2026?
Our dual AI analysis gives BIO-TECHNE Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TECH's free cash flow?
BIO-TECHNE Corp's operating cash flow is $110.0M, with capital expenditures of $11.3M. FCF margin is 16.9%.
How does TECH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.1% (avg: 12%), ROE 3.8% (avg: 15%), current ratio 4.54 (avg: 2).